{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:14Z","timestamp":1787070854173,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Treatment of multiple myeloma (MM) has evolved over decades with the introduction of novel therapeutic strategies. Response rates has significantly improved; however, there is a need for more sensitive techniques to study the residual disease other than conventional means. We evaluated the feasibility and utility of a two-tube six color multiparametric flow cytometry (MFC) assay for measurable residual disease (MRD) detection in MM patients on treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>Pretitrated cocktails containing antibodies against CD38, CD138, CD45, CD19, CD56, CD81, CD27, and cytoplasmic kappa and lambda light chains were used in the combination of two tubes and were acquired on a flow cytometer. Limit of detection was determined through dilution and spiking experiments with a limit of 0.01%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 62 patients screened, 58 patients were included in the final study cohort (day 100 postautologous stem cell transplant and at the end of induction chemotherapy). Twenty-eight patients (48%) revealed the presence of MRD in bone marrow on MFC (median = 0.12, range = 0.01\u20135.89%). Out of 28 MFC-MRD positive patients, only 16 patients showed M band on immunofixation-electrophoresis (IFE) (MRD+\/IFE+, 57%), and rest of them were IFE negative (MRD+\/IFE-, 42%). Patients with MRD positive status at the end of induction chemotherapy or day 100 posttransplant had an inferior overall survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009) and progression-free survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0002) than those with MRD negativity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We have demonstrated the impact of MRD testing in MM using MFC with a long follow-up data, suggesting its routine incorporation in monitoring the disease independent of the immunofixation status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1027_19","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:37Z","timestamp":1639526437000},"page":"1515-1520","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data"],"prefix":"10.4103","volume":"17","author":[{"given":"Praveen","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man Updesh","family":"Singh Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-34-20241021","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"R3-34-20241021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","article-title":"Treatment of multiple myeloma","volume":"103","author":"Barlogie","year":"2004","journal-title":"Blood"},{"key":"R4-34-20241021","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2013.49.2124","article-title":"Minimal residual disease in multiple myeloma","volume":"31","author":"Munshi","year":"2013","journal-title":"J Clin Oncol"},{"key":"R5-34-20241021","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.bbmt.2012.05.009","article-title":"Minimal residual disease in myeloma: Are we there yet?","volume":"18","author":"Hart","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R6-34-20241021","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"R7-34-20241021","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"R8-34-20241021","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"R9-34-20241021","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1309\/AJCP1GYI7EHQYUYK","article-title":"Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma","volume":"132","author":"Gupta","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"R10-34-20241021","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10428194.2016.1228930","article-title":"Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma","volume":"58","author":"Gupta","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"R11-34-20241021","doi-asserted-by":"crossref","first-page":"e20033","DOI":"10.1200\/JCO.2018.36.15_suppl.e20033","article-title":"Prospective evaluation of minimal residual disease in multiple myeloma following autologous stem cell transplantation (ASCT) and consolidation therapy","volume":"36","author":"Mukesh","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"R12-34-20241021","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/j.clml.2019.09.590","article-title":"Standardization of high sensitivity minimal residual disease monitoring in multiple myeloma: An experience in tertiary cancer centre","volume":"19","author":"Subramanian","year":"2019","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"R13-34-20241021","first-page":"e113","article-title":"Is 18F-FDG-PET\/CT a Good MRD marker in patients with multiple myeloma? Comparison and correlation with biochemical markers\/flow cytometry","volume":"17","author":"Yanamandra","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"R14-34-20241021","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2013-05-506170","article-title":"Minimal residual disease testing in multiple myeloma by flow cytometry: Major heterogeneity","volume":"122","author":"Flanders","year":"2013","journal-title":"Blood"},{"key":"R15-34-20241021","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"R16-34-20241021","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"R17-34-20241021","first-page":"1458","article-title":"The role of serum protein electrophoresis in the detection of multiple myeloma: An experience of a corporate hospital","volume":"6","author":"Tripathy","year":"2012","journal-title":"J Clin Diagn Res"},{"key":"R18-34-20241021","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2001-12-0297","article-title":"Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"key":"R19-34-20241021","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","article-title":"Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome","volume":"99","author":"San Miguel","year":"2002","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1027_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:43Z","timestamp":1787067463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1027_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1027_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}